A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma

被引：0
|
作者：
Rodriguez, M
Method, MW
Lewandowski, G
Vaccarello, L
Ansari, RH
机构：
[1] Gynecol Oncol & Pelv Surg Associates, Columbus, OH USA
[2] Michiana Hematol Oncol, South Bend, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5063
引用
收藏
页码：464S / 464S
页数：1
相关论文
共 50 条
  • [31] A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer
    Benigno, B. B.
    Burrell, M. O.
    Daugherty, P.
    Hernandez, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study
    Markman, M
    Blessing, JA
    Alvarez, RD
    Hanjani, P
    Waggoner, S
    Hall, K
    GYNECOLOGIC ONCOLOGY, 2000, 77 (01) : 112 - 115
  • [33] Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study
    Plaxe, SC
    Blessing, JA
    Bookman, MA
    Creasman, WT
    GYNECOLOGIC ONCOLOGY, 2002, 84 (01) : 32 - 35
  • [34] A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
    Viens, P
    Petit, T
    Yovine, A
    Bougnoux, P
    Deplanque, G
    Cottu, PH
    Delva, R
    Lotz, JP
    Belle, SV
    Extra, JM
    Cvitkovic, E
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 429 - 436
  • [35] Weekly topotecan for recurrent platinum resistant ovarian cancer
    Abushahin, Fadi
    Singh, Diljeet K.
    Lurain, John R.
    Grendys, Edward C.
    Rademaker, Alfred W.
    Schink, Julian C.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 53 - 57
  • [36] Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer
    Levy, T
    Inbar, M
    Menczer, J
    Grisaru, D
    Glezerman, M
    Safra, T
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 686 - 690
  • [37] A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
    Covens, A
    Blessing, J
    Bender, D
    Mannel, R
    Morgan, M
    GYNECOLOGIC ONCOLOGY, 2006, 100 (03) : 586 - 590
  • [38] Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer
    Chelariu-Raicu, Anca
    Levenback, Charles
    Slomovitz, Brian
    Wolf, Judith
    Bodurka, Diane C.
    Kavanagh, John J.
    Morrison, Christopher
    Gershenson, David
    Coleman, Robert
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1768 - 1774
  • [39] Phase II prospective study of weekly topotecan and bevacizumab in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
    McGonigle, K. F.
    Muntz, H. G.
    Vuky, J.
    Paley, P. J.
    Veljovich, D. S.
    Gray, H. J.
    Malpass, T. W.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S145 - S145
  • [40] Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer
    Loverix, L.
    Vanderstichele, A.
    Olbrecht, S.
    Van Niewenhuysen, E.
    Van Gorp, T.
    Han, S. N.
    Salihi, R.
    Concin, N.
    Neven, P.
    Busschaert, P.
    Lambrechts, D.
    Vergote, I.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 17 - 18
12345